Skip to main content
Premium Trial:

Request an Annual Quote

OPX Lands $3.6M in Venture Financing to Support Biofuel Genomics

NEW YORK (GenomeWeb News) - OPX Biotechnologies has received $3.6 million in its second round of venture financing, which was led by Mohr Davidow Ventures.
 
Other investors in the round included X/Seed Capital, which provided OPX’s seed financing in June 2007, and Robert Chess, who has been named OPX CEO and chairman.
 
Boulder, Colo.-based OPX is developing genomics technologies designed for microbial biofuel development.
 
OPX’s set of tools and intellectual property, called SCALEs, enable massively parallel full genome search, identification of specific causative genes, and rapid genetic modification and testing, the company said. These tools are used to design new microbes that would improve tolerance, productivity, and specificity for fuel and chemicals production.
 
Chess said the SCALEs technology can “identify the role of each gene and how to modify it to achieve the characteristics needed for specific fuel and chemical products 1,000 to 5,000 times faster than conventional methods.”

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.